Related Experiment Video
Updated: Mar 26, 2026

Quantification of Hypopigmentation Activity In Vitro
Published on: March 6, 2019
Phytochemicals for the Management of Melanoma
Harish Chandra Pal, Katherine Marchiony Hunt, Ariana Diamond
1Department of Dermatology, University of Alabama at Birmingham, Volker Hall, Room 501, 1670 University Blvd., Birmingham, AL, 35294, USA. farrukhafaq@uabmc.edu.
Abstract:
Melanoma claims approximately 80% of skin cancer-related deaths. Its life-threatening nature is primarily due to a propensity to metastasize. The prognosis for melanoma patients with distal metastasis is bleak, with median survival of six months even with the latest available treatments. The most commonly mutated oncogenes in melanoma are BRAF and NRAS accounting approximately 60% and 20% of cases, respectively. In malignant melanoma, accumulating evidence suggests that multiple signaling pathways are constitutively activated and play an important role in cell proliferation, cell survival, epithelial to mesenchymal transition, metastasis and resistance to therapeutic regimens. Phytochemicals are gaining considerable attention because of their low toxicity, low cost, and public acceptance as dietary supplements. Cell culture and animals studies have elucidated several cellular and molecular mechanisms by which phytochemicals act in the prevention and treatment of metastatic melanoma. Several promising phytochemicals, such as, fisetin, epigallocatechin-3-gallate, resveratrol, curcumin, proanthocyanidins, silymarin, apigenin, capsaicin, genistein, indole-3-carbinol, and luteolin are gaining considerable attention and found in a variety of fresh fruits, vegetables, roots, and herbs. In this review, we will discuss the preventive potential, therapeutic effects, bioavailability and structure activity relationship of these selected phytochemicals for the management of melanoma.
Insights
Phytochemicals show promise in preventing and treating metastatic melanoma, a deadly cancer. Research explores their mechanisms, bioavailability, and structure-activity relationships for melanoma management.
Area of Science:
- Oncology
- Pharmacology
- Natural Product Chemistry
Background:
- Melanoma is a deadly skin cancer, responsible for approximately 80% of skin cancer-related deaths, primarily due to its metastatic potential.
- The prognosis for metastatic melanoma is poor, with a median survival of only six months, even with advanced treatments.
- Key oncogenes BRAF and NRAS are frequently mutated in melanoma, driving critical signaling pathways involved in cancer progression and therapeutic resistance.
Purpose of the Study:
- To review the preventive and therapeutic potential of various phytochemicals in managing metastatic melanoma.
- To discuss the mechanisms of action, bioavailability, and structure-activity relationships of selected phytochemicals for melanoma treatment.
- To highlight the role of phytochemicals as potentially low-toxicity, cost-effective adjuncts in melanoma management.
Main Methods:
- Review of existing literature on phytochemicals and their effects on melanoma.
- Analysis of cell culture and animal studies elucidating the cellular and molecular mechanisms of phytochemical action.
- Examination of data on the bioavailability and structure-activity relationships of promising phytochemicals.
Main Results:
- Numerous phytochemicals, including fisetin, epigallocatechin-3-gallate, resveratrol, and curcumin, demonstrate significant potential in preclinical studies.
- These compounds exhibit diverse mechanisms against melanoma, impacting cell proliferation, survival, epithelial-to-mesenchymal transition, and metastasis.
- Evidence suggests phytochemicals can overcome therapeutic resistance pathways activated in malignant melanoma.
Conclusions:
- Phytochemicals represent a promising class of compounds for the prevention and treatment of metastatic melanoma.
- Further research into their bioavailability and structure-activity relationships is crucial for optimizing their therapeutic application.
- These natural compounds offer a potentially safe and accessible complementary approach to conventional melanoma therapies.
Related Concept Videos
Cancer Prevention
Some...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Pigmentation
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules

